Icahn School of Medicine at Mount Sinai
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Icahn School of Medicine at Mount Sinai sits in the top decile of US sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count).
Icahn School of Medicine at Mount Sinai: 708 sponsored US clinical trials, 163 recruiting.
Icahn School of Medicine at Mount Sinai sponsors 708 registered US clinical trials on ClinicalTrials.gov, 163 of them currently recruiting, and 423 completed. 88 of these trials are in Phase 3-4 (later-stage) and 138 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 7 trials.
Top-decile sponsor footprint
Icahn School of Medicine at Mount Sinai ranks in the top decile of sponsors by registered trial count (#48 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
423 of 499 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
708 total, page 9 of 15
Exoskeleton-assisted Walking in SCI Inpatient Rehabilitation
NCT04013997
Hyperbaric Oxygen Therapy for Cognition in Diabetic Elderly at High Dementia Risk
NCT03036254
Project Powerfood: Promoting Food Security, Equity, and Health
NCT03246997
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis
NCT03236792
BVS-OCT Imaging Study
NCT03194711
Study on the Effect of Ibrutinib on High Risk Smoldering Multiple Myeloma Patients
NCT02943473
Side Branch FFR After Provisional Stenting
NCT03115580
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo
NCT03123016
Success of External Cephalic Version Study
NCT03106753
Recall Enhancement Through Treatment With Atomoxetine in MS (RETAIN-MS)
NCT03091400
Ketamine and Nitroprusside for Depression
NCT03102736
Home-based Primary Care for Homebound Seniors
NCT02965508
Integrated Care (iCare) at Mount Sinai to Improve Substance Use Diagnosis and Treatment Practices in HIV Clinic Settings
NCT03092596
Impact of Medicaid Health Home on Patients With Diabetes in New York City
NCT02713321
Transport PLUS Intervention
NCT03046771
Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)
NCT02903160
Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide
NCT03122457
Syncope Decision Aid for Emergency Care
NCT02971163
Hepatitis C Infection in World Trade Center Responders
NCT02982993
Oral Iron for Erythropoietic Protoporphyrias
NCT02979249
Community-based Adolescent Diabetes Prevention Program
NCT02458131
Reward Systems and Food Avoidance in Eating Disorders
NCT02795455
Pilot Diet Study for Multiple Sclerosis
NCT02986893
Post Sustained Virological Response (SVR) Hepatocellular Carcinoma (HCC) Screening
NCT02833298
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
NCT02936206
Multi-level Supermarket Discount Study
NCT04178824
Acupuncture for Post-Operative Pain Control for Patients Undergoing Gynecological Surgery
NCT02855567
Impact of Y90 Radiation Segmentectomy on HCC
NCT03248375
Maternal Loss of Control Eating
NCT03269253
Development of a Polyphenol-rich Dietary Preparation for Treating Veterans With Gulf War Illness
NCT02915237
Programmed Environmental Illumination (PEI) of Hospital Rooms to Prevent/Reduce Cancer-Related Fatigue
NCT03198754
Compare Ultrasound Assisted Cold Therapy and Lidocaine Injection to Treat Morton's Neuroma
NCT02838758
New York City Mobile Interventional Stroke Team
NCT03048292
Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery
NCT02675244
Asthma and Obesity: Observational
NCT03460834
Noom Monitor for Binge Eating
NCT02555553
The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction
NCT02488005
Corticosteroids With Vedolizumab in Crohn's Disease
NCT02324699
Improving Goals of Care Discussion in Advanced Cancer Patients
NCT02374255
Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence
NCT02657993
Effects of Mindfulness Training on Chronic Inflammation in HIV-Infected Adults
NCT02626949
Injecting Botulinum Toxin A Underneath the Skin to Treat Spinal Cord Pain in Patients With Spinal Cord Injury
NCT02736890
Evaluation of HepCure Toolkit to Improve Harvoni Adherence
NCT02740556
Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia
NCT02825212
Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
NCT02684123
Feasibility of Orbital Atherectomy System in Calcified Bifurcation Lesion
NCT03058510
Ketamine and Propofol Combination Versus Propofol for Upper Gastrointestinal Endoscopy
NCT02643979
Cardiovascular Inflammation Reduction Trial - Inflammation Imaging Study
NCT02576067
Botulinum Toxin is a Potential Prophylactic Therapy for Minimizing Post-excisional Scarring (Allergan Botox Scar Study)
NCT02623829
Complications and Outcomes of Pouch Excision
NCT03952195
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 57 |
| Phase 2 | 81 |
| Phase 3 | 21 |
| Phase 4 | 67 |
Therapeutic Areas
What is open in the Icahn School of Medicine at Mount Sinai pipeline
163 recruiting of 708 indexed (23% open); 423 completed (60%).
Phase mix: 88 late (III/IV) vs 138 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Icahn School of Medicine at Mount Sinai: open-pipeline peers nationwide
Peers matched on 708 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Icahn School of Medicine at Mount Sinai sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 708 trials (± recruiting share)
- Sanofi · 713 trials · 10% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
- University of Miami · 721 trials · 20% recruiting
- The Cleveland Clinic · 688 trials · 14% recruiting
Sponsors near 23% open enrollment (± trial volume)
- Clemson University · 23% recruiting · 13 trials
- Liberating Technologies · 23% recruiting · 13 trials
- Rahul Aggarwal · 23% recruiting · 13 trials
- Sequenom · 23% recruiting · 26 trials
Related
What to do with this Icahn School of Medicine at Mount Sinai page
708 registered trials is a research-attention snapshot, not an endorsement of Icahn School of Medicine at Mount Sinai or any single study.
- 163 of Icahn School of Medicine at Mount Sinai's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition Icahn School of Medicine at Mount Sinai studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Icahn School of Medicine at Mount Sinai pipeline card: 708 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.